GSK Announces Vaccine Price Freeze in Support of GAVI Alliance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GSK Announces Vaccine Price Freeze in Support of GAVI Alliance


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 6

GSK reported that it would freeze the prices of its vaccines for five years for developing countries that graduate from GAVI Alliance. By committing to offer GAVI Alliance prices for vaccines against pneumococcal disease, rotavirus and cervical cancer, GSK will support developing country governments as they transition to financing the full cost of their local vaccination programs.

Since its formation in 2000, the GAVI Alliance has helped to fund the immunization of 440 million children in some of the world’s poorest countries. GSK is a long-standing partner of the Alliance and reserves its lowest prices for GAVI-eligible countries, which can be as low as one-tenth of prices in developed countries.

“By 2020, 22 countries with growing economies will graduate from GAVI support. This process allows GAVI to focus resources on the poorest countries, while enabling governments to take increasing responsibility and ownership for vaccination programs over time,” said Andrew Witty, CEO of GSK.

GSK has committed to provide more than 850 million vaccine doses that will help protect up to 300 million children and young girls in the developing world by 2024.

Source: GSK

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here